Ocrelizumab May Represent Roche’s Rebound In Neuroscience
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche plans to file I.V. anti-CD20 antibody ocrelizumab in multiple sclerosis early in 2016, after disclosing that the drug met endpoints in two Phase III studies against Merck Serono’s Rebif.